Filing Details

Items 5(a)-(e) of the Schedule 13D are hereby amended and restated as follows: As of the date hereof, the Reporting Person beneficially owns, in the aggregate, 4,660,228 shares of Common Stock of the Issuer (the "Common Stock"), representing approximately 8.28% of the Issuer's outstanding shares of Common Stock. The Reporting Person beneficially owns shares of Common Stock of the Issuer directly (4,106,727 shares) and through The Wildwood Trust, of which the Reporting Person is Trustee (169,369 shares), and through his spouse, Susan Stiritz (384,132 shares).

The number of shares as to which there is sole power to vote or to direct the vote is 4,276,096. The number of shares as to which there is the shared power to vote or to direct the vote is 384,132. The number of shares as to which there is sole power to dispose or to direct the disposition is 4,276,096. The number of shares as to which there is shared power to dispose or to direct the disposition is 384,132. The Reporting Person shares voting and disposition rights with his spouse with respect to 384,132 shares. Susan Stiritz's address is 790 Briar Hill Road, Belleville, Illinois 62223. Mrs. Stiritz is a professor at Washington University in St. Louis, One Brookings Drive, St. Louis, Missouri 63130. During the last five years, Mrs. Stiritz has not been convicted in a criminal proceeding. During the last five years, Mrs. Stiritz has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction which resulted in her being subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws. Mrs. Stiritz is a citizen of the United States.

The Reporting Person has effected no transactions in the Common Stock of the Issuer within the past sixty days.

Except for the Reporting Person's spouse, no person other than the Reporting Person has the right to receive dividends on, and any proceeds from the disposition of, any shares of Common Stock reported as owned by him in this Item 5 above.

Not applicable.

Item 6 of the Schedule 13D is hereby amended and supplemented by adding the following: On January 30, 2024, the Reporting Person was awarded 2,700 restricted stock units (the "2024 RSUs"). The 2024 RSUs vested on January 30, 2025. The Reporting Person elected to defer settlement of the 2024 RSUs such that settlement will occur in ten annual installments, beginning six months after his separation from service as a director of the Issuer and thereafter following each of the first nine anniversaries of such separation from service, subject to acceleration of all unpaid settlements upon the occurrence of a change in control or the death of the Reporting Person. On February 4, 2025, the Reporting Person was awarded 2,500 restricted stock units (the "2025 RSUs", and together with the 2024 RSUs, the "RSUs"). The 2025 RSUs will vest on February 4, 2026, subject to earlier vesting due to certain events as set forth in the 2025 RSU award agreement. Each 2024 RSU represents a right to receive one share of Common Stock, and each 2025 RSU represents a contingent right to receive one share of Common Stock. The RSUs were awarded to the Reporting Person as a director of the Issuer, in each case subject to a written agreement, the forms of which have been filed with the SEC by the Issuer.

Item 7 of the Schedule 13D is hereby amended to include the following: Exhibit 10.6 Form of Non-Employee Director Restricted Stock Unit Agreement (United States Non-Employee Directors) (Incorporated by reference to Exhibit 10.52 to the Issuer's Form 10-Q filed on May 6, 2022); and Exhibit 10.7 Form of Non-Employee Director Restricted Stock Unit Agreement (United States Non-Employee Directors) (Incorporated by reference to Exhibit 10.53 to the Issuer's Form 10-Q filed on February 7, 2025).